Chest:严重创伤及脓毒症后ARDS风险或与血型相关

2014-04-03 佚名 dxy

ABO糖基转移酶能促进各种多聚糖和糖蛋白抗原的改变,并决定人们的ABO血型。已知A型血与血管性疾病风险增加、循环中炎症以及内皮功能相关蛋白质水平的差异有关。但其与严重创伤和脓毒症患者的急性呼吸窘迫综合征(ARDS)之间是否也存在某种关系目前还不清楚。 来自美国宾夕法尼亚大学佩雷尔曼医学院肺、过敏和重症监护科的Reilly博士等进行的一项研究提示,血型或与严重创伤及脓毒症后ARDS风险相关,文章在

ABO糖基转移酶能促进各种多聚糖和糖蛋白抗原的改变,并决定人们的ABO血型。已知A型血与血管性疾病风险增加、循环中炎症以及内皮功能相关蛋白质水平的差异有关。但其与严重创伤和脓毒症患者的急性呼吸窘迫综合征(ARDS)之间是否也存在某种关系目前还不清楚。

来自美国宾夕法尼亚大学佩雷尔曼医学院肺、过敏和重症监护科的Reilly博士等进行的一项研究提示,血型或与严重创伤及脓毒症后ARDS风险相关,文章在线发表于近期的Chest杂志上。

该项前瞻性队列研究纳入人群包括在一家三级城市的转诊中心和Ⅰ级创伤中心内就诊的2类患者:732例严重外伤后的危重患者及976例患有严重脓毒症的内科患者。研究人员对这些患者分别进行了为期5天的随访,以观察其ARDS的发生状况;并采用多变量logistic回归分析对相关混杂因素进行了校正。

研究的主要结果为:在732例外伤患者中,有197例(27%)发生了ARDS。其中,A型血与白种人ARDS风险增加显著相关,调整后的风险比值比为1.88,但在非裔美国人中则不存在这种相关性。

在976例严重脓毒症患者中,有222例(23%)出现了ARDS。其中,A型血也与白种人ARDS风险的增加相关,调整后比值比为1.67;同样在非裔美国人中也不存在这种相关性。

该研究显示,对于美国白种人而言, A型血与严重创伤及脓毒症患者ARDS风险的增加相关。这表明ABO多聚糖和糖基转移酶对某些患者的ARDS易感性有一定影响。

原始出处

Reilly JP, Meyer NJ, Shashaty MG, Feng R, Lanken PN, Gallop R, Kaplan S, Herlim M, Oz NL, Hiciano I, Campbell A, Holena DN, Reilly MP, Christie JD.ABO Blood Type A is Associated with Increased Risk of Acute Respiratory Distress Syndrome in Caucasians Following both Major Trauma and Severe Sepsis.Chest. 2014 Jan 2.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040209, encodeId=4f1c204020976, content=<a href='/topic/show?id=cb0b1520365' target=_blank style='color:#2F92EE;'>#RDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15203, encryptionId=cb0b1520365, topicName=RDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Apr 20 22:31:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954035, encodeId=0caa1954035ed, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 13 19:31:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929208, encodeId=3763192920821, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jan 02 14:31:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050396, encodeId=6214205039691, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 27 15:31:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335054, encodeId=df88133505424, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 05 04:31:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
    2014-04-20 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=2040209, encodeId=4f1c204020976, content=<a href='/topic/show?id=cb0b1520365' target=_blank style='color:#2F92EE;'>#RDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15203, encryptionId=cb0b1520365, topicName=RDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Apr 20 22:31:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954035, encodeId=0caa1954035ed, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 13 19:31:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929208, encodeId=3763192920821, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jan 02 14:31:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050396, encodeId=6214205039691, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 27 15:31:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335054, encodeId=df88133505424, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 05 04:31:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2040209, encodeId=4f1c204020976, content=<a href='/topic/show?id=cb0b1520365' target=_blank style='color:#2F92EE;'>#RDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15203, encryptionId=cb0b1520365, topicName=RDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Apr 20 22:31:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954035, encodeId=0caa1954035ed, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 13 19:31:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929208, encodeId=3763192920821, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jan 02 14:31:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050396, encodeId=6214205039691, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 27 15:31:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335054, encodeId=df88133505424, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 05 04:31:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
    2015-01-02 Smile2680
  4. [GetPortalCommentsPageByObjectIdResponse(id=2040209, encodeId=4f1c204020976, content=<a href='/topic/show?id=cb0b1520365' target=_blank style='color:#2F92EE;'>#RDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15203, encryptionId=cb0b1520365, topicName=RDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Apr 20 22:31:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954035, encodeId=0caa1954035ed, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 13 19:31:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929208, encodeId=3763192920821, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jan 02 14:31:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050396, encodeId=6214205039691, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 27 15:31:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335054, encodeId=df88133505424, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 05 04:31:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]
    2014-06-27 智者为医08
  5. [GetPortalCommentsPageByObjectIdResponse(id=2040209, encodeId=4f1c204020976, content=<a href='/topic/show?id=cb0b1520365' target=_blank style='color:#2F92EE;'>#RDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15203, encryptionId=cb0b1520365, topicName=RDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Apr 20 22:31:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954035, encodeId=0caa1954035ed, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jun 13 19:31:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929208, encodeId=3763192920821, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jan 02 14:31:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050396, encodeId=6214205039691, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 27 15:31:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335054, encodeId=df88133505424, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 05 04:31:00 CST 2014, time=2014-04-05, status=1, ipAttribution=)]

相关资讯

J NEUROL NEUROSUR PS:罹患脓毒症可致永久认知及脑功能损害

  一项多国联合研究显示,对于从重症监护病房(ICU)出院的患者,无论其是否罹患脓毒症,均可出现多个脑区永久性认知功能损害及非特异性脑功能障碍。与健康对照相比,脓毒症幸存者常出现左侧海马萎缩。医生应对ICU患者进行神经保护治疗,避免发生持久的脑功能改变。论文将发表于《神经病学、神经外科学与精神病学杂志》[J Neurol Neurosurg Psychiatry&nb

瞿洪平:脓毒症液体复苏:宜“早”“足”“湿”

脓毒症患者需要液体复苏,但大量液体输入有液体蓄积的风险,进而可能导致严重后果。于是,面对脓毒症患者,是否补液?怎么补液?补多少?补什么?已成为重症监护病房(ICU)医生需要慎重思量的问题。在前不久召开的第七次全国重症医学大会上,举办了两场辩论,分别就脓毒症是否需要液体复苏,以及复苏时是否用胶体进行了讨论。在脓毒症早期,足量的液体复苏可改善患者预后,减少之后的液体需求及进一步脏器损伤,而并不显著

脓毒症急性肾损伤发病机制和诊断治疗的新认识

急性肾损伤(AKI)可表现为由多种原因造成的肾功能急剧下降,是影响多器官多系统的临床重症。按照AKI的RIFLE'危险(Risk)(损伤(Injury)(衰竭(Failure)(丧失(Loss)(终末期肾病(End-stagerenaldisease)]定义,约8%的住院患者、超过50%的危重病患者合并有AKI,而罹患AKI并需要透析干预者占所有危重病患者的5%,其病死率高达30%〜60%。

CDSR:β-内酰胺类加氨基糖苷类抗生素有害

   优化治疗脓毒症的抗生素方案势在必行。2014年1月发表在Cochrane Database Syst Rev的系统评价显示,由于全因死亡率并未改变,且显著增加肾毒性的风险,在治疗脓毒症时,不应鼓励在β-内酰胺类药物中添加氨基糖苷类药物, 背景:优化治疗脓毒症的抗生素方案势在必行。与β-内酰胺类抗生素单药治疗相比,β-内酰胺类抗生素联合氨基糖苷类抗生素可能有一定的优势。 目

Lancet Infect Dis:降钙素原可作为脓毒症的诊断标志物

降钙素原是一个可确认细菌感染的标志物。为评估降钙素原在诊断危重患者脓毒症上的准确性和临床价值,德国耶拿大学的Peter Schlattmann教授等做了一项研究,发现降钙素原可作为病危患者中脓毒症的诊断标志物。该研究在线发表在 Lancet infectious diseases上。 研究搜索了各大数据库上2012年12月21日之前所有的资料,并列出了确认的原始研究。这些研究涵盖了以英语、德语或

JAMA:羟乙基淀粉不能为脓毒症患者带来益处

丹麦和瑞士学者检索循证医学图书馆、MEDLINE等数据库,对2012年9月前发表的比较羟乙基淀粉(HES)130/0.38-0.45 和晶体液或人白蛋白对脓毒症患者液体复苏效果和安全性的9 项随机对照临床试验(涉及3456例患者)进行分析。结果显示,与晶体液或白蛋白相比,使用HES130/0.38-0.45 对脓毒症患者进行液体复苏,增加肾脏替代治疗、急性肾功能衰竭和红细胞输注风险,且出现严重不良